ATE4980T1 - Morpholinderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung. - Google Patents

Morpholinderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.

Info

Publication number
ATE4980T1
ATE4980T1 AT80303473T AT80303473T ATE4980T1 AT E4980 T1 ATE4980 T1 AT E4980T1 AT 80303473 T AT80303473 T AT 80303473T AT 80303473 T AT80303473 T AT 80303473T AT E4980 T1 ATE4980 T1 AT E4980T1
Authority
AT
Austria
Prior art keywords
lower alkyl
morpholine derivatives
manufacture
pharmaceutical compositions
compositions containing
Prior art date
Application number
AT80303473T
Other languages
English (en)
Inventor
Alan Chapman White
Edwin Trevor Edington
Original Assignee
John Wyeth & Brother Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Wyeth & Brother Limited filed Critical John Wyeth & Brother Limited
Application granted granted Critical
Publication of ATE4980T1 publication Critical patent/ATE4980T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Lubricants (AREA)
AT80303473T 1979-10-20 1980-10-02 Morpholinderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung. ATE4980T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7936502 1979-10-20

Publications (1)

Publication Number Publication Date
ATE4980T1 true ATE4980T1 (de) 1983-10-15

Family

ID=10508675

Family Applications (1)

Application Number Title Priority Date Filing Date
AT80303473T ATE4980T1 (de) 1979-10-20 1980-10-02 Morpholinderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.

Country Status (17)

Country Link
US (1) US4360519A (de)
EP (1) EP0027695B1 (de)
JP (1) JPS5665880A (de)
KR (2) KR840002427B1 (de)
AT (1) ATE4980T1 (de)
AU (1) AU531586B2 (de)
CA (1) CA1126731A (de)
DE (1) DE3065304D1 (de)
DK (1) DK151800C (de)
ES (1) ES496074A0 (de)
FI (1) FI803277L (de)
GB (1) GB2061272B (de)
GR (1) GR70235B (de)
IE (1) IE50355B1 (de)
MY (1) MY8500468A (de)
PT (1) PT71940B (de)
ZA (1) ZA806017B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125793B (en) * 1982-08-19 1985-10-02 Wyeth John & Brother Ltd Morpholine derivatives
GB8305638D0 (en) * 1983-03-01 1983-03-30 Wyeth John & Brother Ltd Morpholine derivatives
FR2553412B1 (fr) * 1983-10-17 1986-03-21 Lafon Labor Derives de 4-alkyl-2-methyl-2-phenyl-morpholine, procede de preparation et utilisation en therapeutique
GB8418657D0 (en) * 1984-07-21 1984-08-22 Beecham Group Plc Compounds
FR2581383A1 (fr) * 1985-05-03 1986-11-07 Cerm Cent Europ Rech Mauvernay 2-alkyl-2-aryl morpholines substituees, leur preparation et les compositions pharmaceutiques les contenant
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9108629D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
MXPA05006728A (es) * 2002-12-19 2005-09-08 Merck & Co Inc Amidas sustituidas.
EP2332919A3 (de) 2003-06-17 2011-10-19 Arena Pharmaceuticals, Inc. Verfahren zur Herstellung von 3-Benzazepinen
CA2646044A1 (en) 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
WO2008070111A2 (en) 2006-12-05 2008-06-12 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
EP2288585A1 (de) 2008-03-04 2011-03-02 Arena Pharmaceuticals, Inc. Verfahren zur herstellung von mit dem 5-ht2c-agonisten (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin verwandten zwischenprodukten
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
CA2800220C (en) 2010-05-21 2019-04-30 Research Triangle Institute Phenylmorpholines and analogues thereof
JP5952267B2 (ja) 2010-05-21 2016-07-13 リサーチ・トライアングル・インスティチュート 薬物依存を処置するためのヒドロキシブプロピオン類似体（政府支援研究または開発）
US9045431B2 (en) 2010-06-02 2015-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-HT2C receptor agonists
US9365521B2 (en) 2010-09-01 2016-06-14 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-HT2C agonists
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
KR20180094131A (ko) 2010-09-01 2018-08-22 에자이 알앤드디 매니지먼트 가부시키가이샤 신장 손상을 갖는 개체에 대한 로카세린의 투여
SG10201506874UA (en) 2010-09-01 2015-10-29 Arena Pharm Inc Modified-release dosage forms of 5-ht2c agonists useful for weight management
MX2015004532A (es) 2012-10-09 2016-01-20 Arena Pharm Inc Metodo de control del peso.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2997469A (en) * 1961-08-22 Preparation of substituted
US2835669A (en) * 1958-05-20 Process for the production of substi-
US3112311A (en) * 1957-04-05 1963-11-26 Geigy Chem Corp 2-phenyl-5, 6-dimethyl-morpholines and 2-phenyl-5, 6-tetramethylene-morpholines
US3296076A (en) * 1962-06-11 1967-01-03 Boehringer Sohn Ingelheim Pilomotor shaving compositions and method of using same
GB1336732A (en) * 1970-10-28 1973-11-07 Istituto Gentili Spa Pisa Diethanolamine derivatives
GB1452701A (en) * 1974-05-07 1976-10-13 Ici Ltd Morpholine derivatives

Also Published As

Publication number Publication date
AU531586B2 (en) 1983-09-01
PT71940B (pt) 1981-08-31
US4360519A (en) 1982-11-23
CA1126731A (en) 1982-06-29
DK441080A (da) 1981-04-21
DK151800B (da) 1988-01-04
ES8107201A1 (es) 1981-10-01
MY8500468A (en) 1985-12-31
GB2061272B (en) 1983-08-10
EP0027695A1 (de) 1981-04-29
KR840002428B1 (ko) 1984-12-27
KR840002427B1 (ko) 1984-12-27
IE801995L (en) 1981-04-20
GR70235B (de) 1982-09-01
KR830004277A (ko) 1983-07-09
JPS5665880A (en) 1981-06-03
IE50355B1 (en) 1986-04-02
GB2061272A (en) 1981-05-13
PT71940A (en) 1980-11-01
FI803277L (fi) 1981-04-21
DK151800C (da) 1988-06-06
ZA806017B (en) 1982-04-28
ES496074A0 (es) 1981-10-01
DE3065304D1 (en) 1983-11-17
AU6292280A (en) 1981-04-30
EP0027695B1 (de) 1983-10-12

Similar Documents

Publication Publication Date Title
ATE4980T1 (de) Morpholinderivate, sie enthaltende pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung.
ATE7226T1 (de) 4-benzyl- und 4-benzoyl-imidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE9793T1 (de) 5-oxo- und 5-thioxoproline, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE10368T1 (de) Uracilderivate, verfahren zu ihrer herstellung und eine diese enthaltende pharmazeutische zubereitung.
ATE2265T1 (de) Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
ATE53032T1 (de) 2-thiazolylimidazo(1,2-a)pyrimidine und ihre salze, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
ATE13765T1 (de) 2-(1,4-benzodioxan-2-ylalkyl)-imidazole, deren herstellung und sie enthaltende pharmazeutische mittel.
DE3274860D1 (en) Triazoloquinazolones and their salts, process and intermediates for preparing them, their use as medicines and compositions containing them
ES480111A1 (es) Procedimiento para la preparacion de nuevos derivados de 2- iminoimidazolidina.
ATE11915T1 (de) Benzothiazolderivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung.
ATE48994T1 (de) Benzimidazol-derivat, verfahren zu seiner herstellung und pharmazeutische zusammensetzung.
ATE37368T1 (de) Benzothiazolon-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE5961T1 (de) N-acylpeptid-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE22284T1 (de) 2-aminomethyl-6-sulfamoylphenolderivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
ES8200859A1 (es) Un procedimiento para la preparacion de derivados de ciclo- hexadieno
ES487631A1 (es) Procedimiento para la obtencion de hexahidro-1,4-oxazepinas
ES8304532A1 (es) "procedimiento de preparacion de derivados de etanolamina".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee